Pembrolizumab Monotherapy in Relapsed Hepatocellular Carcinoma Post Living Donor Liver Transplantation and Sorafenib
Nasr F., Al Ghoche A., Diab S., Maddah J., Mansour L., Kassem A.,Gheith A.K.
Published online 2018 November 12,
Despite of the high incidence of hepatocellular carcinoma (HCC), treatment strategies stays restrained. New treatment aspects remain a necessity to improve overall survival of patients.
Here, we report for the first time a 2 years complete remission of hepatocellular carcinoma with pembrolizumab after failure of sorafenib and progression after liver transplantation.
Immunotherapy became a field of interest in HCC for researchers and clinicians in order to establish new immunotherapy modalities that improve response to treatment of HCC.Leave a reply